De substantial contributions to conception and design, or acquisition of data > 자유게시판

• 목록
• 답변
• 게시판 리스트 옵션
  • 수정
  • 삭제

De substantial contributions to conception and design, or acquisition of Rosiglitazone data, or analysis and interpretation of data; LJ, FP, MB, L? CD, DB, PM and SRD were involved in drafting the manuscript or revising it critically for important intellectual content; MB, L? CD and DB have been involved in analysing and calculating the data. LJ, FP, MB, L? CD, DB, PM and SRD agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript. Competing interests The authors declare that they have no competing interests. Consent for publication All authors have read and given their consent for publication of the manuscript. Ethical approval and consent to participate The regional ethics committee at the University Hospital, Ume? Sweden, approved this study, and all participants gave their written informed consent when donating blood samples. Author details 1 Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 2Department of Public Health and Clinical Medicine/Rheumatology, Ume?University, Ume? Sweden. Received: 13 April 2016 Accepted: 20 MayReferences 1. Klareskog L, Padyukov L, Lorentzen J, Alfredsson L. Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006;2:425?3. 2. Anzilotti C, Pratesi F, Tommasi C, Migliorini P. Peptidylarginine deiminase 4 and citrullination in health and disease. Autoimmun Rev. 2010;9:158?0. 3. Pruijn GJ, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/6811518 2010;12:203. 4. Uysal H, Nandakumar KS, Kessel C, et al. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol Rev. 2010;233:9?3. 5. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580?. 6. Rantap -Dahlqvist S, de Jong BAW, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741?. 7. Nielen MMJ, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380?. 8. Brink M, Hansson M, Mathsson L, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum. 2013;65:899?10. 9. Suwannalai P, van de Stadt LA, Radner H, et al. Avidity maturation of anticitrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum. 2012;64:1323?. 10. van der Woude D, Alemayehu WG, Verduijn W, et al. Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nat Genet. 2010;42:814?. author reply 816. 11. Croia C, Serafini B, Bombardieri M, et al. Epstein-Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis. Ann Rheum Dis. 2013;72:1559?8. 12. Toussirot E, Roudier J. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus:.